DuPont™ Care4U™ 2’-fucosyllactose (2’-FL) has significant effects on the microbiota and metabolite production under simulated infant gut conditions.
KANTVIK, Finland, Oct. 8, 2019 – Continuing its leading research on human milk oligosaccharides (HMOs), DuPont released the findings of a new study showing that Care4U™ 2’-FL, a DuPont product, beneficially changes microbiota composition and the production of microbial metabolites in comparison to galacto-oligosaccharides (GOS) and lactose. The effects elicited to microbiota and metabolite composition by 2’-FL were between the responses elicited by GOS and lactose, which indicates that 2’-FL is selectively fermented by the infant microbes.
“Our previous in vitro cultivation experiments, as well as literature, indicated that 2’-FL is selectively utilized by only certain types of bifidobacteria and Bacteroides species, and this type of modelling with a complex microbiota is a step ahead in our journey to understand the prebiotic mechanisms of 2’-FL,” indicated Krista Salli, M.Sc., Scientist, DuPont Nutrition & Biosciences.
“This study exemplifies the utility of the DuPont™ Enteromix® infant gut simulator to compare the fermentation of the carbohydrates between each other,” said Heli Anglenius, Ph.D., Senior Scientist, DuPont Nutrition & Biosciences. “Over the years, the Enteromix® gut simulator developed in-house in Kantvik, Finland, has been used successfully for a multitude of studies with fecal microbiota sampled from adults, and this study demonstrates its applicability to studies where the microbiota is obtained from infants. This is a great continuation for more than 20 years of expertise using our own pre-clinical modelling.”
Among the study’s other achievements was the comparison of 2’-FL to GOS and lactose.
“While this study was done under simulated gut conditions, it showed the differences between the carbohydrates, especially in the production of microbial metabolites,” said Ratna Mukherjea, Ph.D., Technical Fellow and Global Research and Development Leader-Human Milk Oligosaccharides (HMO), DuPont Nutrition & Biosciences. “These kind of study approaches can give more understanding on the how HMOs can be utilized by the microbiota with a method that is not invasive, which is important especially in the case of infants.”
You can read more about this study at https://www.nature.com/articles/s41598-019-49497-z.
About DuPont™ Danisco®
DuPont™ Danisco® is the brand for a range of products that help provide enhanced bioprotection, an improved nutritional profile, and better taste and texture with greater cost efficiency and lower environmental impact, meeting the needs of manufacturers of food and beverages and dietary supplements. Through the work of the global network of food scientists and technologists in DuPont, the Danisco® range is supported by a uniquely broad spectrum of know-how across applications and processing.
About DuPont Nutrition & Biosciences
DuPont Nutrition & Biosciences applies expert science to advance market-driven, healthy and sustainable solutions for the food, beverage, dietary supplement and pharmaceutical industries. We also use cutting-edge biotechnology across a range of markets to advance bio-based solutions to meet the needs of a growing population, while protecting our environment for future generations. We are innovative solvers who help our customers turn challenges into high-value business opportunities. For more information: www.dupontnutritionandbiosciences.com or www.biosciences.dupont.com.
DuPont (NYSE: DD) is a global innovation leader with technology-based materials, ingredients and solutions that help transform industries and everyday life. Our employees apply diverse science and expertise to help customers advance their best ideas and deliver essential innovations in key markets including electronics, transportation, construction, water, health and wellness, food, and worker safety. More information can be found at www.dupont.com.